A Closer Look At PBM Spread Pricing

Spread pricing by pharmacy benefit managers (PBMs) is often portrayed in a negative light due to its perceived impact on drug costs and pharmacy reimbursements. However, it’s essential to explore the nuances of this practice to understand its full scope and potential benefits. While the criticism of spread pricing is valid in certain contexts, there’s another side to this coin that deserves attention. It is critical to dive into the complexities of spread pricing in order to find a balanced perspective on its role in the pharmaceutical industry.
The Future of Healthcare Is Data-Driven: Xevant’s Predictive Analytics Platform Is Paving the Way for Personalized Medicine

Xevant‘s cutting-edge approach to healthcare analytics is setting a new standard in personalized medicine. Leveraging big data and predictive analytics, Xevant provides actionable insights that revolutionize patient care and cost management. The platform’s technology not only speeds up critical pharmacy analysis but also significantly enhances the accuracy and relevance of healthcare decisions. This transformative impact has positioned Xevant as a leader in the healthcare technology sector, paving the way for a more efficient and patient-centric healthcare system.
How Did You Find Your Purpose? – Featuring Xevant’s Chief of Staff, Jaylyn Palmer

“What excites me most about my work is finding myself in a place that values taking care of its people as the foundation of a successful business. Recognizing the human element within the organization and fostering a supportive environment is key. I love to witness the positive impact of embracing authenticity and vulnerability, allowing individuals to be their true selves in an atmosphere where they feel safe to challenge themselves and grow. This approach aligns with my personal belief that genuine care for people leads to both personal and collective success.”
Government Patent Seizures Could Curb Costs But Could Have Unintended Consequences

The Biden administration has announced a new framework to enforce the government’s “march-in” rights to seize patents on drugs developed with taxpayer funding if it deems that their prices are unreasonably high.
The CFO of 2030 – Featuring Xevant’s Pete Tantillo

Today’s finance chiefs predict their future, from the role of AI to the changing workplace.